Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
J&J reached out to vaccine rivals to study blood clot risk, WSJ reports » 09:33
04/16/21
04/16
09:33
04/16/21
09:33
JNJ

Johnson & Johnson

$160.44 /

+0.49 (+0.31%)

, PFE

Pfizer

$37.61 /

+0.45 (+1.21%)

, MRNA

Moderna

$159.85 /

-0.25 (-0.16%)

, AZN

AstraZeneca

$50.84 /

+0.97 (+1.95%)

Johnson & Johnson…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
PFE Pfizer
$37.61 /

+0.45 (+1.21%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
MRNA Moderna
$159.85 /

-0.25 (-0.16%)

04/15/21 Piper Sandler
Moderna price target raised to $234 from $208 at Piper Sandler
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

  • 19
    May
JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

Recommendations
Carlisle price increases point to strong demand, says Jefferies » 09:13
04/16/21
04/16
09:13
04/16/21
09:13
CSL

Carlisle

$171.91 /

-0.89 (-0.52%)

Jefferies analyst Saree…

Jefferies analyst Saree Boroditsky noted that Carlisle announced a price increase of up to 10% on its coatings and waterproofing products effective May 15, which follows a price increase announced earlier in the month on metal products ranging from 8%-30% effective May 3. Carlisle had previously implemented price increases on membranes and insulation and on metal products effective March 1, while competitor GAF has also been increasing prices, said Boroditsky, who also notes recent channel checks on the commercial roofing outlook for 2021 were positive. The analyst, who thinks Carlisle's guidance for the full year 2021 is likely conservative based on the multiple rounds of price increases and her recent channel checks, has a Buy rating and $180 price target on the shares.

ShowHide Related Items >><<
CSL Carlisle
$171.91 /

-0.89 (-0.52%)

CSL Carlisle
$171.91 /

-0.89 (-0.52%)

04/12/21 Oppenheimer
Carlisle price target raised to $188 from $175 at Oppenheimer
04/12/21 Longbow
Carlisle downgraded to Neutral from Buy at Longbow
03/25/21
Fly Intel: Top five analyst upgrades
03/25/21 Loop Capital
Carlisle upgraded to Buy from Hold at Loop Capital
CSL Carlisle
$171.91 /

-0.89 (-0.52%)

On The Fly
Fly Intel: Pre-market Movers » 08:58
04/16/21
04/16
08:58
04/16/21
08:58
STT

State Street

$86.53 /

-0.13 (-0.15%)

, ALXN

Alexion

$157.53 /

+2.25 (+1.45%)

, DRNA

Dicerna

$28.54 /

+0.73 (+2.62%)

, EBET

Esports Technologies

$36.05 /

+12.95 (+56.06%)

, CFG

Citizens Financial

$44.66 /

-0.845 (-1.86%)

, ALLY

Ally Financial

$47.65 /

-0.105 (-0.22%)

, PPG

PPG

$153.99 /

+3.17 (+2.10%)

, MS

Morgan Stanley

$80.89 /

+0.11 (+0.14%)

, BK

BNY Mellon

$48.02 /

-0.6 (-1.23%)

, EDIT

Editas Medicine

$41.02 /

-0.5 (-1.20%)

, AZN

AstraZeneca

$50.84 /

+0.97 (+1.95%)

Check out this morning's…

ShowHide Related Items >><<
STT State Street
$86.53 /

-0.13 (-0.15%)

PPG PPG
$153.99 /

+3.17 (+2.10%)

MS Morgan Stanley
$80.89 /

+0.11 (+0.14%)

EDIT Editas Medicine
$41.02 /

-0.5 (-1.20%)

DRNA Dicerna
$28.54 /

+0.73 (+2.62%)

CFG Citizens Financial
$44.66 /

-0.845 (-1.86%)

BK BNY Mellon
$48.02 /

-0.6 (-1.23%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

ALXN Alexion
$157.53 /

+2.25 (+1.45%)

ALLY Ally Financial
$47.65 /

-0.105 (-0.22%)

STT State Street
$86.53 /

-0.13 (-0.15%)

04/09/21 Deutsche Bank
State Street price target raised to $100 from $97 at Deutsche Bank
04/07/21 Barclays
State Street price target raised to $104 from $99 at Barclays
04/01/21 Wells Fargo
State Street price target raised to $90 from $83 at Wells Fargo
04/01/21 Morgan Stanley
State Street price target raised to $103 from $102 at Morgan Stanley
ALXN Alexion
$157.53 /

+2.25 (+1.45%)

03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
03/23/21 SVB Leerink
Alexion downgraded to Market Perform from Outperform at SVB Leerink
02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
DRNA Dicerna
$28.54 /

+0.73 (+2.62%)

04:53 Today Goldman Sachs
Dicerna initiated with a Buy at Goldman Sachs
03/18/21
Dicerna to hold a webinar on DCR-AUD disorder
03/02/21 H.C. Wainwright
Dicerna price target raised to $40 from $35 at H.C. Wainwright
EBET Esports Technologies
$36.05 /

+12.95 (+56.06%)

CFG Citizens Financial
$44.66 /

-0.845 (-1.86%)

04/09/21 Jefferies
Citizens Financial price target raised to $47 from $42 at Jefferies
04/07/21 Barclays
Citizens Financial price target raised to $54 from $49 at Barclays
04/01/21 Deutsche Bank
Citizens Financial price target raised to $50 from $44 at Deutsche Bank
03/30/21 Stephens
Citizens Financial price target raised to $54 from $45 at Stephens
ALLY Ally Financial
$47.65 /

-0.105 (-0.22%)

04/15/21 JPMorgan
Ally Financial price target raised to $54 from $48 at JPMorgan
04/13/21 Wells Fargo
Ally Financial price target raised to $57 from $51 at Wells Fargo
04/12/21 BofA
Ally Financial reinstated with a Buy at BofA
04/08/21 Evercore ISI
Ally Financial initiated with an Outperform at Evercore ISI
PPG PPG
$153.99 /

+3.17 (+2.10%)

04/15/21 Citi
Citi opens '30-day negative catalyst watch' on Axalta, PPG
04/07/21 Wells Fargo
PPG price target raised to $173 from $165 at Wells Fargo
03/15/21 Credit Suisse
PPG assumed with a Neutral at Credit Suisse
01/26/21 BofA
PPG upgraded to Buy from Neutral at BofA
MS Morgan Stanley
$80.89 /

+0.11 (+0.14%)

04/09/21 JMP Securities
Goldman Sachs price target raised to $400 from $338 at JMP Securities
04/07/21 Barclays
Morgan Stanley price target raised to $98 from $95 at Barclays
04/01/21 Deutsche Bank
Morgan Stanley price target raised to $79 from $68 at Deutsche Bank
04/01/21 UBS
Morgan Stanley price target raised to $92 from $84 at UBS
BK BNY Mellon
$48.02 /

-0.6 (-1.23%)

04/09/21 Deutsche Bank
BNY Mellon price target raised to $54 from $50 at Deutsche Bank
04/07/21 Barclays
BNY Mellon price target raised to $57 from $55 at Barclays
03/26/21 JPMorgan
JPMorgan sees BNY Mellon, Wells Fargo among banks with most buyback capacity
03/24/21
Fly Intel: Top five analyst upgrades
EDIT Editas Medicine
$41.02 /

-0.5 (-1.20%)

04:56 Today Goldman Sachs
Editas Medicine initiated with a Sell at Goldman Sachs
03/22/21 Credit Suisse
Editas Medicine initiated with an Outperform at Credit Suisse
03/17/21 Guggenheim
Editas Medicine assumed with a Neutral at Guggenheim
03/01/21 Barclays
Editas Medicine downgraded to Equal Weight from Overweight at Barclays
AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
STT State Street
$86.53 /

-0.13 (-0.15%)

PPG PPG
$153.99 /

+3.17 (+2.10%)

MS Morgan Stanley
$80.89 /

+0.11 (+0.14%)

EDIT Editas Medicine
$41.02 /

-0.5 (-1.20%)

DRNA Dicerna
$28.54 /

+0.73 (+2.62%)

CFG Citizens Financial
$44.66 /

-0.845 (-1.86%)

BK BNY Mellon
$48.02 /

-0.6 (-1.23%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

ALXN Alexion
$157.53 /

+2.25 (+1.45%)

ALLY Ally Financial
$47.65 /

-0.105 (-0.22%)

  • 15
    Apr
  • 21
    Jan
  • 24
    Jun
STT State Street
$86.53 /

-0.13 (-0.15%)

MS Morgan Stanley
$80.89 /

+0.11 (+0.14%)

CFG Citizens Financial
$44.66 /

-0.845 (-1.86%)

BK BNY Mellon
$48.02 /

-0.6 (-1.23%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

STT State Street
$86.53 /

-0.13 (-0.15%)

PPG PPG
$153.99 /

+3.17 (+2.10%)

MS Morgan Stanley
$80.89 /

+0.11 (+0.14%)

EDIT Editas Medicine
$41.02 /

-0.5 (-1.20%)

DRNA Dicerna
$28.54 /

+0.73 (+2.62%)

BK BNY Mellon
$48.02 /

-0.6 (-1.23%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

ALXN Alexion
$157.53 /

+2.25 (+1.45%)

ALLY Ally Financial
$47.65 /

-0.105 (-0.22%)

PPG PPG
$153.99 /

+3.17 (+2.10%)

MS Morgan Stanley
$80.89 /

+0.11 (+0.14%)

EDIT Editas Medicine
$41.02 /

-0.5 (-1.20%)

CFG Citizens Financial
$44.66 /

-0.845 (-1.86%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

ALXN Alexion
$157.53 /

+2.25 (+1.45%)

ALLY Ally Financial
$47.65 /

-0.105 (-0.22%)

Hot Stocks
AstraZeneca reports U.S. clearance of proposed acquisition of Alexion » 07:12
04/16/21
04/16
07:12
04/16/21
07:12
AZN

AstraZeneca

$50.84 /

+0.97 (+1.95%)

, ALXN

Alexion

$157.53 /

+2.25 (+1.45%)

AstraZeneca's (AZN)…

AstraZeneca's (AZN) proposed acquisition of Alexion Pharmaceuticals (ALXN) has "achieved an important step toward completion," having cleared U.S. Federal Trade Commission review following the conclusion of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, the company announced. "The announcement follows competition clearances in Canada, Brazil, Russia and other countries globally, with a full list available on astrazeneca.com. Additional global regulatory clearances are pending, including but not limited to the UK, EU and Japan," AstraZeneca said.

ShowHide Related Items >><<
AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

ALXN Alexion
$157.53 /

+2.25 (+1.45%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
ALXN Alexion
$157.53 /

+2.25 (+1.45%)

03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
03/23/21 SVB Leerink
Alexion downgraded to Market Perform from Outperform at SVB Leerink
02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

ALXN Alexion
$157.53 /

+2.25 (+1.45%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

ALXN Alexion
$157.53 /

+2.25 (+1.45%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

ALXN Alexion
$157.53 /

+2.25 (+1.45%)

Hot Stocks
Genentech announces new Ocrevus analyses at AAN meeting » 05:20
04/16/21
04/16
05:20
04/16/21
05:20
RHHBY

Roche

$41.85 /

+0.21 (+0.50%)

Genentech, a member of…

Genentech, a member of the Roche Group, announced new Ocrevus analyses supporting its benefit on disease progression in early-stage relapsing-remitting multiple sclerosis, or RRMS, and primary progressive MS, or PPMS, as well as demonstrating persistence and adherence to twice-yearly dosing. These data are being presented virtually at the American Academy of Neurology, or AAN. Ocrevus is the number one prescribed MS medication in the U.S. for patients starting a new treatment, and more than 200,000 people have now been treated with Ocrevus globally. Ocrevus treatment provided consistent benefit over one year in patients who were recently diagnosed with RRMS and had not received prior disease modifying treatment, or DMT, in an interim analysis of open-label Phase IIIb study ENSEMBLE. After 48 weeks, 85% of Ocrevus-treated patients achieved no evidence of disease activity. The average annualized relapse rate across all patients was very low and their mean change in Expanded Disability Status Scale score, or EDSS, from baseline significantly improved from 1.71 to 1.55. Additionally, neurofilament light chain, or NfL, a marker of nerve cell damage, was reduced to nearly healthy control levels with Ocrevus treatment. The safety profile of Ocrevus in this trial was consistent with its overall favorable safety profile. Ocrevus treatment significantly slowed accumulation of atrophied T2-lesion volume, or aT2-LV, compared with placebo at 120 weeks in a post-hoc analysis of the ORATORIO study in PPMS. AT2-LV is a measure that reflects the volume of T2 lesions in brain tissue that is replaced by cerebrospinal fluid, and is believed to be a marker of disease progression in MS. People with PPMS experience three to five times higher accumulation of aT2-LV than people with relapsing MS and these data suggest that Ocrevus may favorably impact the underlying progressive biology of MS. Approximately 80% of patients adhered to twice-yearly dosing of Ocrevus after their second year of treatment compared with other DMTs, which were grouped by administration route, in a new analysis of U.S. commercial and insurance claims databases. Ocrevus also had the highest proportion of patients persist with therapy at two years. Ocrevus is approved in 95 countries across North America, South America, the Middle East, Eastern Europe, as well as in Australia, Switzerland, the United Kingdom and the EU.

ShowHide Related Items >><<
RHHBY Roche
$41.85 /

+0.21 (+0.50%)

RHHBY Roche
$41.85 /

+0.21 (+0.50%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
RHHBY Roche
$41.85 /

+0.21 (+0.50%)

RHHBY Roche
$41.85 /

+0.21 (+0.50%)

RHHBY Roche
$41.85 /

+0.21 (+0.50%)

Conference/Events
American College of Medical Genetics & Genomics » 04:55
04/16/21
04/16
04:55
04/16/21
04:55
APLT

Applied Therapeutics

$16.73 /

+0.16 (+0.97%)

, BNGO

Bionano Genomics

$6.12 /

-0.305 (-4.75%)

, CNTG

Centogene

$11.67 /

-0.73 (-5.89%)

, DGX

Quest Diagnostics

$129.23 /

+2.03 (+1.60%)

, FIXX

Homology Medicines

$7.03 /

-0.19 (-2.63%)

, FOLD

Amicus

$10.33 /

+0.345 (+3.46%)

, ILMN

Illumina

$401.83 /

+4.65 (+1.17%)

, NTRA

Natera

$106.24 /

+4.81 (+4.74%)

, NVTA

Invitae

$39.08 /

+ (+0.00%)

, RARE

Ultragenyx

$109.71 /

+1.59 (+1.47%)

, SNY

Sanofi

$50.68 /

+0.4199 (+0.84%)

, TAK

Takeda Pharmaceutical

$17.21 /

+0.155 (+0.91%)

, UA

Under Armour

$18.32 /

-0.115 (-0.62%)

, XFOR

X4 Pharmaceuticals

$8.77 /

-0.21 (-2.34%)

Annual Clinical Genetics…

Annual Clinical Genetics Virtual Meeting of ACMG to be held on April 13-16. Webcast Link

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$8.77 /

-0.21 (-2.34%)

UA Under Armour
$18.32 /

-0.115 (-0.62%)

TAK Takeda Pharmaceutical
$17.21 /

+0.155 (+0.91%)

SNY Sanofi
$50.68 /

+0.4199 (+0.84%)

RARE Ultragenyx
$109.71 /

+1.59 (+1.47%)

NVTA Invitae
$39.08 /

+ (+0.00%)

NTRA Natera
$106.24 /

+4.81 (+4.74%)

ILMN Illumina
$401.83 /

+4.65 (+1.17%)

FOLD Amicus
$10.33 /

+0.345 (+3.46%)

FIXX Homology Medicines
$7.03 /

-0.19 (-2.63%)

DGX Quest Diagnostics
$129.23 /

+2.03 (+1.60%)

CNTG Centogene
$11.67 /

-0.73 (-5.89%)

BNGO Bionano Genomics
$6.12 /

-0.305 (-4.75%)

APLT Applied Therapeutics
$16.73 /

+0.16 (+0.97%)

APLT Applied Therapeutics
$16.73 /

+0.16 (+0.97%)

11/17/20 Barclays
Applied Therapeutics price target lowered to $44 from $64 at Barclays
10/08/20 Truist
Applied Therapeutics initiated with a Buy at Truist
10/08/20 Truist
Applied Therapeutics initiated with a Buy at Truist
04/22/20
Fly Intel: Top five analyst initiations
BNGO Bionano Genomics
$6.12 /

-0.305 (-4.75%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
CNTG Centogene
$11.67 /

-0.73 (-5.89%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
DGX Quest Diagnostics
$129.23 /

+2.03 (+1.60%)

03/12/21 Baird
Quest Diagnostics downgraded to Neutral from Outperform at Baird
01/29/21 Citi
Quest Diagnostics price target raised to $158 from $151 at Citi
12/17/20 Morgan Stanley
Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
12/17/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
FIXX Homology Medicines
$7.03 /

-0.19 (-2.63%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
FOLD Amicus
$10.33 /

+0.345 (+3.46%)

04/14/21 Cantor Fitzgerald
Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
04/13/21 Cantor Fitzgerald
Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
ILMN Illumina
$401.83 /

+4.65 (+1.17%)

04/06/21 Wells Fargo
Illumina price target raised to $330 from $300 at Wells Fargo
04/06/21 Canaccord
Illumina price target raised to $460 from $445 at Canaccord
04/05/21 Evercore ISI
Evercore upgrades Edwards to Outperform ahead of its 'best pipeline cycle'
03/31/21 Canaccord
Canaccord upgrades Illumina, says worth owning with or without Grail
NTRA Natera
$106.24 /

+4.81 (+4.74%)

03/10/21 Piper Sandler
Natera, Genentech start Phase 3 trial using Signatera, says Piper Sandler
02/26/21 Piper Sandler
Natera price target raised to $150 from $127 at Piper Sandler
01/27/21 Truist
Natera initiated with a Buy at Truist
01/19/21 BTIG
Natera price target raised to $135 from $112 at BTIG
NVTA Invitae
$39.08 /

+ (+0.00%)

04/05/21 Oppenheimer
Oppenheimer upgrades Invitae on valuation, sees potential high $50s stock
04/05/21 Oppenheimer
Invitae upgraded to Outperform from Perform at Oppenheimer
02/18/21 Ladenburg
Invitae upgraded to Buy with $58 price target at Ladenburg
02/18/21 Ladenburg
Invitae upgraded to Buy from Neutral at Ladenburg
RARE Ultragenyx
$109.71 /

+1.59 (+1.47%)

03/24/21 Stifel
Stifel remains optimistic on GTX-102 and Ultragenyx ahead of 'important' update
03/01/21 Stifel
Ultragenyx resumed with a Buy at Stifel
02/12/21 Wedbush
Ultragenyx price target raised to $130 from $113 at Wedbush
02/12/21 Barclays
Ultragenyx price target raised to $186 from $176 at Barclays
SNY Sanofi
$50.68 /

+0.4199 (+0.84%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
TAK Takeda Pharmaceutical
$17.21 /

+0.155 (+0.91%)

04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21
Fly Intel: Top five analyst downgrades
04/05/21 Barclays
Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
04/05/21 Jefferies
Takeda Pharmaceutical downgraded to Hold from Buy at Jefferies
UA Under Armour
$18.32 /

-0.115 (-0.62%)

02/22/21 Williams Capital
Under Armour initiated with a Hold at Williams Trading
02/19/21 Oppenheimer
Opco upgrades Under Armour on potential return to 'outsized' sales growth
02/19/21 Oppenheimer
Under Armour upgraded to Outperform from Perform at Oppenheimer
02/11/21 Jefferies
Under Armour price target raised to $30 from $25 at Jefferies
XFOR X4 Pharmaceuticals
$8.77 /

-0.21 (-2.34%)

12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
XFOR X4 Pharmaceuticals
$8.77 /

-0.21 (-2.34%)

UA Under Armour
$18.32 /

-0.115 (-0.62%)

TAK Takeda Pharmaceutical
$17.21 /

+0.155 (+0.91%)

SNY Sanofi
$50.68 /

+0.4199 (+0.84%)

RARE Ultragenyx
$109.71 /

+1.59 (+1.47%)

NVTA Invitae
$39.08 /

+ (+0.00%)

NTRA Natera
$106.24 /

+4.81 (+4.74%)

ILMN Illumina
$401.83 /

+4.65 (+1.17%)

FOLD Amicus
$10.33 /

+0.345 (+3.46%)

FIXX Homology Medicines
$7.03 /

-0.19 (-2.63%)

DGX Quest Diagnostics
$129.23 /

+2.03 (+1.60%)

CNTG Centogene
$11.67 /

-0.73 (-5.89%)

BNGO Bionano Genomics
$6.12 /

-0.305 (-4.75%)

APLT Applied Therapeutics
$16.73 /

+0.16 (+0.97%)

  • 07
    Apr
  • 12
    Feb
  • 22
    Jan
  • 20
    Jan
  • 08
    Jan
  • 29
    Oct
  • 11
    Sep
  • 10
    Jul
UA Under Armour
$18.32 /

-0.115 (-0.62%)

SNY Sanofi
$50.68 /

+0.4199 (+0.84%)

ILMN Illumina
$401.83 /

+4.65 (+1.17%)

FOLD Amicus
$10.33 /

+0.345 (+3.46%)

UA Under Armour
$18.32 /

-0.115 (-0.62%)

TAK Takeda Pharmaceutical
$17.21 /

+0.155 (+0.91%)

SNY Sanofi
$50.68 /

+0.4199 (+0.84%)

NVTA Invitae
$39.08 /

+ (+0.00%)

NTRA Natera
$106.24 /

+4.81 (+4.74%)

ILMN Illumina
$401.83 /

+4.65 (+1.17%)

FOLD Amicus
$10.33 /

+0.345 (+3.46%)

FIXX Homology Medicines
$7.03 /

-0.19 (-2.63%)

DGX Quest Diagnostics
$129.23 /

+2.03 (+1.60%)

BNGO Bionano Genomics
$6.12 /

-0.305 (-4.75%)

APLT Applied Therapeutics
$16.73 /

+0.16 (+0.97%)

UA Under Armour
$18.32 /

-0.115 (-0.62%)

TAK Takeda Pharmaceutical
$17.21 /

+0.155 (+0.91%)

NVTA Invitae
$39.08 /

+ (+0.00%)

ILMN Illumina
$401.83 /

+4.65 (+1.17%)

FOLD Amicus
$10.33 /

+0.345 (+3.46%)

DGX Quest Diagnostics
$129.23 /

+2.03 (+1.60%)

BNGO Bionano Genomics
$6.12 /

-0.305 (-4.75%)

Yesterday
Hot Stocks
GlaxoSmithKline, Vir Biotechnology announce EMA review of VIR-7831 » 09:54
04/15/21
04/15
09:54
04/15/21
09:54
GSK

GlaxoSmithKline

$38.02 /

+1.895 (+5.25%)

, VIR

Vir Biotechnology

$45.02 /

-0.36 (-0.79%)

GlaxoSmithKline (GSK) and…

GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) announced that the European Medicines Agency, or EMA, has started a review of VIR-7831, an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents aged 12 years and over and weighing at least 40 kg with COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19. The review is being carried out by the EMA's Committee for Human Medicinal Products, or CHMP, and will provide EU-wide recommendations for national authorities who may take evidence-based decisions on the early use of the medicine, ahead of any formal Marketing Authorization Application. "This week, the Australian Therapeutic Goods Administration (TGA), part of the Department of Health, granted VIR-7831 a provisional determination. VIR-7831 is the first anti-SARS-CoV-2 monoclonal antibody to have been granted this designation which provides a formal and transparent mechanism for accelerating the registration of promising new medicines with preliminary clinical data. VIR-7831 is an investigational compound and has not been granted a marketing authorisation anywhere in the world. An Emergency Use Authorization application for VIR-7831 has been submitted to the US Food and Drug Administration," the companies said.

ShowHide Related Items >><<
VIR Vir Biotechnology
$45.02 /

-0.36 (-0.79%)

GSK GlaxoSmithKline
$38.02 /

+1.895 (+5.25%)

GSK GlaxoSmithKline
$38.02 /

+1.895 (+5.25%)

03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
03/23/21 SVB Leerink
GlaxoSmithKline downgraded to Market Perform from Outperform at SVB Leerink
03/08/21 JPMorgan
JPMorgan double downgrades AnaptysBio back to Underweight after trial miss
VIR Vir Biotechnology
$45.02 /

-0.36 (-0.79%)

03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
03/03/21 Goldman Sachs
Vir Biotechnology price target lowered to $59 from $61 at Goldman Sachs
03/03/21 H.C. Wainwright
Vir Biotechnology selloff a 'terrific buying opportunity,' says H.C. Wainwright
VIR Vir Biotechnology
$45.02 /

-0.36 (-0.79%)

GSK GlaxoSmithKline
$38.02 /

+1.895 (+5.25%)

  • 08
    Jul
GSK GlaxoSmithKline
$38.02 /

+1.895 (+5.25%)

VIR Vir Biotechnology
$45.02 /

-0.36 (-0.79%)

GSK GlaxoSmithKline
$38.02 /

+1.895 (+5.25%)

GSK GlaxoSmithKline
$38.02 /

+1.895 (+5.25%)

Options
Unusually active option classes on open April 15th » 09:40
04/15/21
04/15
09:40
04/15/21
09:40
HPE

HP Enterprise

$15.78 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$36.12 /

+ (+0.00%)

, INO

Inovio

$8.85 /

+ (+0.00%)

, MLCO

Melco Resorts & Entertainment

$19.53 /

+ (+0.00%)

, BX

Blackstone

$78.01 /

+ (+0.00%)

, SPCE

Virgin Galactic

$26.65 /

+ (+0.00%)

, TSM

TSMC

$120.87 /

+ (+0.00%)

, AI

C3.ai

$68.41 /

-0.07 (-0.10%)

, V

Visa

$222.14 /

+ (+0.00%)

, DOCU

DocuSign

$225.45 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Hewlett Packard Enterprise (HPE), GlaxoSmithKline (GSK), Inovio (INO), Melco Resorts (MLCO), Blackstone (BX), Virgin Galactic (SPCE), Taiwan Semi (TSM), C3 AI (AI), Visa (V), and DocuSign (DOCU).

ShowHide Related Items >><<
V Visa
$222.14 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

INO Inovio
$8.85 /

+ (+0.00%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

AI C3.ai
$68.41 /

-0.07 (-0.10%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

04/08/21 Morgan Stanley
HP Enterprise price target raised to $17 from $15.50 at Morgan Stanley
03/26/21 JPMorgan
HP Enterprise price target raised to $18 from $17 at JPMorgan
03/10/21
Fly Intel: Top five analyst upgrades
03/10/21 Daiwa
HP Enterprise upgraded to Outperform from Neutral at Daiwa
GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
03/23/21 SVB Leerink
GlaxoSmithKline downgraded to Market Perform from Outperform at SVB Leerink
03/08/21 JPMorgan
JPMorgan double downgrades AnaptysBio back to Underweight after trial miss
INO Inovio
$8.85 /

+ (+0.00%)

03/23/21
Fly Intel: Top five analyst initiations
03/23/21 BofA
Inovio initiated with a Neutral at BofA
03/02/21 Piper Sandler
Piper lowers Inovio target to $7 after 'decidedly negative' update
02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

02/25/21 CLSA
Melco Resorts & Entertainment upgraded to Outperform from Underperform at CLSA
01/07/21 Macquarie
Melco Resorts & Entertainment downgraded to Neutral from Outperform at Macquarie
11/17/20 JPMorgan
Melco Resorts & Entertainment price target raised to $25 from $23 at JPMorgan
11/05/20 Roth Capital
Roth Capital trims price target on 'go-to Macau name' Melco Resorts to $30
BX Blackstone
$78.01 /

+ (+0.00%)

04/12/21 Barclays
Blackstone price target raised to $85 from $75 at Barclays
04/09/21 Deutsche Bank
Blackstone price target raised to $66 from $61 at Deutsche Bank
03/19/21
Fly Intel: Top five analyst downgrades
03/18/21 Oppenheimer
Blackstone downgraded to Perform on valuation at Oppenheimer
SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

04/12/21 Bernstein
Virgin Galactic initiated with a Market Perform at Bernstein
03/16/21 Truist
Truist starts 'uniquely positioned' Virgin Galactic at Buy with $50 price target
03/16/21 Truist
Virgin Galactic initiated with a Buy at Truist
03/03/21 BofA
Virgin Galactic price target raised to $50 from $35 at BofA
TSM TSMC
$120.87 /

+ (+0.00%)

04/12/21
Fly Intel: Top five analyst initiations
04/12/21 Atlantic Equities
TSMC initiated with a Neutral at Atlantic Equities
04/01/21 DA Davidson
Onto Innovation price target raised to $80 from $75 at DA Davidson
03/29/21 Citi
TSMC recent selloff brings 'enhanced buying opportunity,' says Citi
AI C3.ai
$68.41 /

-0.07 (-0.10%)

03/02/21 Canaccord
C3.ai price target lowered to $120 from $140 at Canaccord
01/04/21 KeyBanc
C3.ai initiated with a Sector Weight at KeyBanc
01/04/21 Wedbush
Wedbush bullish on C3.ai, initiates with an Outperform
01/04/21 Canaccord
C3.ai initiated with a Hold at Canaccord
V Visa
$222.14 /

+ (+0.00%)

03/19/21 JPMorgan
Visa has 'navigated heavy regulatory oversight' before, says JPMorgan
03/19/21 Wells Fargo
Visa selloff on WSJ story likely a buying opportunity, says Wells Fargo
03/19/21 Barclays
Visa, MasterCard facing new DOJ scrutiny on debt practices, says Barclays
03/16/21 Morgan Stanley
Visa price target raised to $253 from $233 at Morgan Stanley
DOCU DocuSign
$225.45 /

+ (+0.00%)

04/08/21 BofA
BofA reinstates DocuSign at Buy with $250 price target
04/08/21 BofA
DocuSign reinstated with a Buy at BofA
03/29/21 Daiwa
DocuSign initiated with a Buy at Daiwa
03/25/21 DA Davidson
DocuSign still confident in reaching $5B or more in revenue, says DA Davidson
V Visa
$222.14 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

INO Inovio
$8.85 /

+ (+0.00%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

AI C3.ai
$68.41 /

-0.07 (-0.10%)

  • 21
    Jan
  • 09
    Dec
  • 13
    Oct
  • 06
    Aug
  • 03
    Jun
  • 20
    May
V Visa
$222.14 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

V Visa
$222.14 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

INO Inovio
$8.85 /

+ (+0.00%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

AI C3.ai
$68.41 /

-0.07 (-0.10%)

V Visa
$222.14 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

INO Inovio
$8.85 /

+ (+0.00%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

AI C3.ai
$68.41 /

-0.07 (-0.10%)

Conference/Events
Canaccord to hold a virtual conference » 09:39
04/15/21
04/15
09:39
04/15/21
09:39
ONCY

Oncolytics

$3.06 /

-0.08 (-2.55%)

, SESN

Sesen Bio

$2.35 /

+0.015 (+0.64%)

, OLMA

Olema Oncology

$35.84 /

+3.56 (+11.03%)

, SQZ

SQZ Biotechnologies

$13.06 /

-0.12 (-0.91%)

, APTO

Aptose Biosciences

$5.20 /

+0.09 (+1.76%)

, BCEL

Atreca

$12.42 /

+0.83 (+7.16%)

, BNTX

BioNTech

$132.52 /

+3.11 (+2.40%)

Horizons in Oncology…

Horizons in Oncology Virtual Conference to be held on April 15.

ShowHide Related Items >><<
SQZ SQZ Biotechnologies
$13.06 /

-0.12 (-0.91%)

SESN Sesen Bio
$2.35 /

+0.015 (+0.64%)

ONCY Oncolytics
$3.06 /

-0.08 (-2.55%)

OLMA Olema Oncology
$35.84 /

+3.56 (+11.03%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

APTO Aptose Biosciences
$5.20 /

+0.09 (+1.76%)

ONCY Oncolytics
$3.06 /

-0.08 (-2.55%)

02/17/21 H.C. Wainwright
Oncolytics initiated with a Buy at H.C. Wainwright
05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
SESN Sesen Bio
$2.35 /

+0.015 (+0.64%)

02/17/21 Canaccord
Sesen Bio price target raised to $7 from $5 at Canaccord
02/16/21 Canaccord
Sesen Bio price target raised to $7 from $5 at Canaccord
02/16/21 Jefferies
Jefferies doubles target on Sesen Bio to $6 on 'optimal scenario'
01/25/21 Canaccord
Sesen Bio a must-own small cap for 2021, says Canaccord
OLMA Olema Oncology
$35.84 /

+3.56 (+11.03%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
SQZ SQZ Biotechnologies
$13.06 /

-0.12 (-0.91%)

03/30/21 Brookline
SQZ Biotechnologies initiated with a Buy at Brookline
01/07/21 Evercore ISI
SQZ Biotechnologies initiated with an Outperform at Evercore ISI
11/24/20 Stifel
SQZ Biotechnologies initiated with a Buy at Stifel
11/24/20 BofA
SQZ Biotechnologies initiated with a Buy at BofA
APTO Aptose Biosciences
$5.20 /

+0.09 (+1.76%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
BCEL Atreca
$12.42 /

+0.83 (+7.16%)

02/08/21 Jefferies
Atreca initiated with a Buy at Jefferies
08/12/20 Stifel
Volatility in Atreca shares creates 'interesting' opportunity, says Stifel
07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
SESN Sesen Bio
$2.35 /

+0.015 (+0.64%)

ONCY Oncolytics
$3.06 /

-0.08 (-2.55%)

OLMA Olema Oncology
$35.84 /

+3.56 (+11.03%)

BCEL Atreca
$12.42 /

+0.83 (+7.16%)

APTO Aptose Biosciences
$5.20 /

+0.09 (+1.76%)

  • 12
    Feb
  • 19
    Nov
  • 30
    Oct
  • 23
    Jul
  • 16
    Jul
  • 16
    Jul
BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

SQZ SQZ Biotechnologies
$13.06 /

-0.12 (-0.91%)

SESN Sesen Bio
$2.35 /

+0.015 (+0.64%)

OLMA Olema Oncology
$35.84 /

+3.56 (+11.03%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

APTO Aptose Biosciences
$5.20 /

+0.09 (+1.76%)

OLMA Olema Oncology
$35.84 /

+3.56 (+11.03%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

Hot Stocks
Xoma adds three Affimed ICE programs to royalty portfolio » 09:14
04/15/21
04/15
09:14
04/15/21
09:14
XOMA

Xoma

$37.39 /

-0.175 (-0.47%)

, AFMD

Affimed

$10.33 /

+0.465 (+4.71%)

XOMA Corporation (XOMA)…

XOMA Corporation (XOMA) announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. (AFMD) innate cell engager programs for which XOMA could receive future economics. In 2006, Affimed licensed certain XOMA technologies to further its research and discovery efforts. AFM13, which has Orphan Drug designation from the U.S. Food and Drug Administration, is a first-in-class CD30/CD16A ICE generated from Affimed's ROCK platform that induces specific and selective killing of CD30-positive tumor cells by engaging and activating natural killer cells and macrophages, thereby leveraging the power of the body's own innate immune system. Affimed currently is studying AFM13 in combination with cord blood-derived allogeneic natural killer cells in cooperation with the MD Anderson Cancer Center in Houston. AFM24 is a tetravalent, bispecific EGFR- and CD16A-binding ICE also generated from Affimed's ROCK platform. AFM24 uses the cytotoxic potential of the innate immune system by redirecting and activating NK cells and macrophages to kill EGFR-positive cancer cells through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, respectively. XOMA is eligible to receive undisclosed payments on future commercial sales of each of the three ICE molecules and any pre-loaded NK cells containing the ICE molecules. Additionally, XOMA is eligible to receive an undisclosed milestone for each program on achieving marketing approval.

ShowHide Related Items >><<
XOMA Xoma
$37.39 /

-0.175 (-0.47%)

AFMD Affimed
$10.33 /

+0.465 (+4.71%)

XOMA Xoma
$37.39 /

-0.175 (-0.47%)

01/19/21 H.C. Wainwright
Xoma price target raised to $56 from $30 at H.C. Wainwright
AFMD Affimed
$10.33 /

+0.465 (+4.71%)

04/12/21 BMO Capital
Affimed price target raised to $15 from $12 at BMO Capital
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
XOMA Xoma
$37.39 /

-0.175 (-0.47%)

  • 13
    Jan
AFMD Affimed
$10.33 /

+0.465 (+4.71%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.